Forensic Analysis · General / Diversified · as of Jun 28, 2026
CapsoVision, Inc (CV)
A forensic read on CapsoVision, Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-30.1
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-184.2%
ROE
$376M
Market cap
CapsoVision, Inc earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -30.1, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-147%Return on invested capital.Return on invested capital is -147% and slipping from -105% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
+1115.6%/yrShare-count dilution.Diluted share count changed +1116% over the last 1 years to FY2025 (+1115.6%/yr). The count is GROWING — existing holders are being diluted. That's ~1115.6% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~1116%.
67d DSOReceivables vs revenue.Days sales outstanding moved from 62 to 67 days FY2024→FY2025 (receivables +25% vs revenue +15%). Receivables are creeping up relative to sales — watch the trend.
Key fundamentals
Net Margin-186.8%
Free Cash Flow$-23.0M
Latest Revenue$13.6M
Return on Equity-190.9%
Revenue Growth YoY+15.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on CapsoVision, Inc:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CV's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown